The role of medications in the employment of people with Schizophrenia

Journal of Rehabilitation

Volumn 65, Issue 4, 1999, Pages 9-16

  Bond, Gary R ^a   Meyer, Piper S ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0040625915     PISSN: 00224154     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Alverson, M., Becker, D. R., & Drake, R. E. (1995). An ethnographic study of coping strategies used by people with severe mental illness participating in supported employment. Psychosocial Rehabilitation Journal, 18(4), 115-128.
2. Anthony, W. A., & Blanch, A. (1987). Supported employment for persons who are psychiatrically disabled: An historical and conceptual perspective. Psychosocial Rehabilitation Journal, 11(2), 5-23.
3. Anthony, W. A., & Jansen, M. A. (1984). Predicting the vocational capacity of the chronically mentally ill: Research and implications. American Psychologist, 39, 537-544.
4. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
5. Ballus, C. (1997). Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia. Schizophrenia Research, 28, 247-255.
6. Becker, D. R., & Drake, R. E. (1994). Individual placement and support: A community mental health center approach to vocational rehabilitation. Community Mental Health Journal, 30, 193-206.
7. Bell, M. D., & Lysaker, P. H. (1995). Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatric Services, 46, 508-10.
8. Bernstein, J. G. (1995). Handbook of drug therapy in psychiatry (3rd ed.). St. Louis: Mosby.
9. Binder, R. L., McNiel, D. E., & Sandberg, D. A. (1998). A naturalistic study of clinical use of risperidone. Psychiatric Services, 49, 524-526.
10. Bond, G. R., Drake, R. E., Becker, D. R., & Mueser, K. T. (in press). Effectiveness of psychiatric rehabilitation approaches for employment of people with severe mental illness. Journal of Disability Policy Studies.
11. Bond, G. R., Drake, R. E., Mueser, K. T., & Becker, D. R. (1997). An update on supported employment for people with severe mental illness. Psychiatric Services, 48, 335-346.
12. Bond, G. R., Meyer, P., Rollins, A., McCoy, M., Herbeck, D., & Rowan, D. (1998). The impact of atypical antipsychotics on vocational outcomes in a psychiatric rehabilitation agency. (Final Report to Eli Lilly). Indianapolis, IN: Indiana University-Purdue University Indianapolis.
13. Braitman, A., Counts, P., Davenport, R., Zurlinden, B., Rogers, M., Clauss, J., Kulkarni, A., Kymla, J., & Montgomery, L. (1995). Comparison of barriers to employment for unemployed and employed clients in a case management program: An exploratory study. Psychiatric Rehabilitation Journal. 19(1), 3-18.
14. Casey, D. E. (1996). Side effect profiles of new antipsychotic agents. Journal of Clinical Psychiatry, 57(Suppl 11), 46-52.
15. Center for Mental Health. (1996). Moving ahead with a vision: Psychopharmacology and work (videotape). Anderson, IN: Center for Mental Health.
16. Chiles, J. A., Miller, A. L., Crismon, M. L., Rush, A., J., Krasnoff, A. S., & Shon, S. S. (1999). The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatric Services, 50, 69-74.
17. Collaborative Working Group on Clinical Trial Evaluations. (1998). Evaluating the effects of antipsychotics on cognition in schizophrenia. Journal of Clinical Psychiatry, 59 (Supplement 12), 35-40.
18. Corrigan, P. W., Reedy, P., Thadani, D., & Ganet, M. (1995). Correlates of participation and completion in a job club for clients with psychiatric disability. Rehabilitation Counseling Bulletin, 39, 42-53.
19. Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196-201.
20. Crow, T. J. (1980). Molecular pathology of schizophrenia: More than one disease process? British Medical Journal, 280, 66-68.
21. Davis, J. M. (1980). Antipsychotic drugs. In H. I. Kaplan, A. M. Freedman, & B. J. Sadock (Eds.), Comprehensive textbook of psychiatry (Vol. 3, pp. 2257-2289). Baltimore: Williams & Wilkins.
22. Dawkins, K., Lieberman, J. A., Lebowitz, B. D., & Hsiao, J. K. (1999). Antipsychotics: Past and future. Proceedings of the National Institute of Mental Health division of services and intervention research workshop. Schizophrenia Bulletin, 25, 395-404.
23. Dixon, L. B., Lehman, A. E, & Levine, J. (1995). Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21, 567-577.
24. Draine, J., & Solomon, P. (1994). Explaining attitudes toward medication compliance among a seriously mentally ill population. Journal of Nervous and Mental Disease, 182, 50-54.
25. Drake, R. E., McHugo, G. J., Bebout, R. R., Becker, D. R., Harris, M., Bond, G. R., & Quimby, E. (1999). A randomized clinical trial of supported employment for inner-city patients with severe mental illness. Archives of General Psychiatry, 56, 627-633.
26. Drake, R. E., McHugo, G. J., Becker, D. R., Anthony, W. A., & Clark, R. E. (1996). The New Hampshire study of supported employment for people with severe mental illness: Vocational outcomes. Journal of Consulting and Clinical Psychology, 64, 391-399.
27. Dunham, C. (1982). Don't talk about your delusions on the job: An experience with competitive job placement in psychiatric rehabilitation. Psychosocial Rehabilitation Journal, 5(1), 41-46.
28. Franz, M., Lis, S., Pluddemann, K., & Gallhofer, B. (1997). Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 170, 422-425.
29. Gitlin, M. J. (1996). The psychotherapist's guide to psychopharmacology (2nd ed.). New York: Free Press.
30. Glazer, W. M. (1998). Formulary decisions and health economics. Journal of Clinical Psychiatry, 59(Suppl 19), 23-29.
31. Goodyear, R. K. (1983). Patterns of counselor attitudes toward disability groups. Rehabilitation Counseling Bulletin, 26, 181-184.
32. Gorman, J. M. (1998). The essential guide to psychiatric drugs. St. Martin's Press.
33. Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
34. Green, M. F., & Nuechterlein, K. H. (1999). Conceptual frame works: Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin, 25, 309-319.
35. Grilli Tissot, M. C., & Elkis, H. (1999). Meta-analyses of randomized controlled trials which compared the effect of typical versus atypical neuroleptics on negative symptoms in schizophrenia [Abstract]. Schizophrenia Research, 36, 281.
36. Hamilton, S. H., Genduso, L. A., & Revicki, D. A. (1998, February). Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders. Paper presented at the Ninth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland.
37. Hayes, R. L., & Halford, W. K. (1996). Time use of unemployed and employed single male schizophrenic subjects. Schizophrenia Bulletin, 22, 659-669.
38. Hirsch, S. R., & Barnes, T. R. E. (1995). The clinical treatment of schizophrenia with antipsychotic medication. In S. R. Hirsch & D. R. Weinberger (Eds.), Schizophrenia (pp. 443-468). Cambridge, MS: Blackwell Science.
39. Hoffmann, H., & Kupper, Z. (1997). Relationships between social competence, psychopathology and work performance and their predictive value for vocational rehabilitation of schizophrenic outpatients. Schizophrenia Research, 23, 69-79.
40. Hogarty, G. E., & Goldberg, S. C. (1973). Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry, 28, 54-64.
41. Hogarty, G. E., McEvoy, J. P., Munetz, M., DiBarry, A. L., Bartone, P., Gather, R., Cooley, S. J., Ulrich, R. F., Carter, M., & Madonia, M. J. (1988). Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Archives of General Psychiatry, 45, 797-805.
42. Jacobs, H. E., Wissusik, D., Collier, R., Stackman, D., & Burkeman, D. (1992). Correlations between psychiatric disabilities and vocational outcome. Hospital and Community Psychiatry, 43, 365-369.
43. Jaeger, J., & Douglas, E. (1992). Neuropsychiatric rehabilitation for persistent mental illness. Psychiatric Quarterly, 63, 71-94.
44. Janicak, P. G., Davis, J. M., Preskorn, S. H., & Ayd, F. J. (1997). Principles and practice of psychopharmacotherapy (2nd ed.). Baltimore: Williams & Wilkins.
45. Johnson, D. A. (1977). Treatment of chronic schizophrenia. Drugs, 14, 291-299.
46. Kane, J. M., & Mayerhoff, D. (1989). Do negative symptoms respond to pharmacological treatment? British Journal of Psychiatry, 155 (Supplement 7), 115-118.
47. Kane, J. M., Woerner, M., & Borenstein, M. (1986). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22, 254-258.
48. Kaplan, H. I., & Sadock, B. J. (1996). Pocket handbook of psychiatric drug treatment (2nd ed.). Lippincott: Williams & Wilkins.
49. Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin, 25, 201-222.
50. Kirsh, B. (1996). Influences on the process of work integration: The consumer perspective. Canadian Journal of Community Mental Health, 15, 21-37.
51. Lehman, A. F., Steinwachs, D. M., Dixon, L. B., Goldman, H. H., Osher, F., Postrado, L., Scott, J. E., Thompson, J. W., Fahey, M., Fischer, P., Kasper, J. A., Lyles, A., Skinner, E. A., Buchanan, R., Carpenter, W. T., Jr., Levine, J., McGlynn, E. A., Rosenheck, R., & Zito, J. (1998a). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10.
52. Lehman, A. F., Steinwachs, D. M., & PORT Co-Investigators. (1998b). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Survey. Schizophrenia Bulletin, 24, 11-20.
53. Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Journal of Clinical Psychiatry, 57 (Suppl 11), 68-71.
54. Lindström, L. H., & Lundberg, T. (1997). Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients. European Psychiatry, 12 (Supplement 5), 353s-355s.
55. Link, B. G., Cullen, F. T., Frank, J., & Wozniak, J. F. (1987). The social rejection of former mental patients: Understanding why labels matter. American Journal of Sociology, 92, 1461-1500.
56. Littrell, K. (1995). Maximizing schizophrenia treatment outcomes: A model for integration. Psychiatric Rehabilitation Journal, 19(1), 75-77.
57. Lysaker, P., & Bell, M. (1995). Negative symptoms and vocational impairment in schizophrenia: Repeated measurements of work performance over six months. Acta Psychiatrica Scandinavica, 91, 205-208.
58. Lysaker, P., Bell, M., & Beam-Goulet, J. (1995). Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatry Research, 56, 45-51.
59. Mancuso, L. L. (1990). Reasonable accommodation for workers with psychiatric disabilities. Psychosocial Rehabilitation Journal, 14(2), 3-19.
60. Marder, S. R. (1996). Management of treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry, 57 (Suppl 11), 26-30.
61. Marder, S. R., & May, P. R. (1986). Benefits and limitations of neuroleptics - and other forms of treatment - in schizophrenia. American Journal of Psychotherapy, 40, 357-369.
62. Marder, S. R., Wirshing, W. C., & Ames, D. (1997). Overview of antipsychotic medications. In D. C. Dunner (Ed.), Current psychiatric therapy II (pp. 211-216). Philadelphia: W. B. Saunders Company.
63. Marrone, J., Morgan, J., Scripture, D., & Grossman, M. (1984). Serving the severely psychiatrically disabled client within the VR system. Psychosocial Rehabilitation Journal, 8(2), 5-23.
64. Marshak, L. E., Bostick, D., & Turton, L. J. (1990). Closure outcomes for clients with psychiatric disabilities served by the vocational rehabilitation system. Rehabilitation Counseling Bulletin, 33, 247-250.
65. Meltzer, H. Y. (1995). Atypical antipsychotic drug therapy for treatment resistant schizophrenia. In S. R. Hirsch & D. R. Weinberger (Eds.), Schizophrenia (pp. 485-502). Cambridge, MA: Blackwell Science.
66. Meltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
67. Meltzer, H. Y., Cola, P., & Way, L. (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.
68. Meltzer, H. Y., & McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233-255.
69. Mintz, J., Mintz, L. L. Hwang, S. S., & Uijtdehaage, S. (1997). Work outcomes in depression and schizophrenia (Final Report MH51112-02). Los Angeles: UCLA Department of Psychiatry.
70. Moller, H. J., Muller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995). A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American Risperidone Study. European Archives of Psychiatry & Clinical Neuroscience, 245, 45-49.
71. Mueser, K. T., & Gingerich, S. (1994). Coping with schizophrenia: A guide for families. Oakland, CA: New Harbinger Publications.
72. Noordsy, D., & O'Keefe, C. (in press). Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC setting. Journal of Clinical Psychiatry.
73. Nurnberg, H. G., & Levine, P. E. (1986). Schizophrenia and antipsychotic drugs. Comprehensive Therapy, 12, 42-52.
74. Preston, J. D., O'Neal, J. H., & Talaga, M. C. (1998). Consumer's guide to psychiatric drugs. Oakland, CA: New Harbinger Publications.
75. Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., Thomas, J., Henderson, W., & Charney, D. (1998). Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry, 55, 618-625.
76. Sajatovic, M., & Schulz, S. C. (1997). Schizophrenia. In D. L. Dunner (Ed.), Current psychiatric therapy II (2nd ed., pp. 181-191). Philadelphia: W.B. Saunders Company.
77. Song, F. (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 11, 65-71.
78. Spohn, H. E., & Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 367-380.
79. Stip, E., & Lussier, I. (1996). The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry, 41(8 Suppl 2), S35-S40.
80. Streicker, S. K., Amdur, M., & Dincin, J. (1986). Educating patients about psychiatric medications: Failure to enhance compliance. Psychosocial Rehabilitation Journal, 9(4), 15-28.
81. Tamminga, C. A. (1997). The promise of new drugs for schizophrenia treatment. Canadian Journal of Psychiatry, 42, 265-273.
82. Tollefson, G. D., & Sanger, T. M. (1997). Negative symptoms: A path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466-74.
83. Torrey, E. F. (1986). Management of chronic schizophrenic outpatients. Psychiatric Clinics of North America, 9, 143-151.
84. Torrey, E. F. (1995). Surviving schizophrenia: A manual for families, consumers, and providers (3rd ed.). New York: HarperCollins.
85. Torrey, W. C., Bebout, R., Kline, J., Becker, D. R., Alverson, M., & Drake, R. E. (1998). Practice guidelines for clinicians working in programs providing integrated vocational and clinical services for persons with severe mental disorders. Psychiatric Rehabiliation Journal, 21(4), 388-393.
86. Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C., Jr., & Tollefson, G. D. (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407-418.
87. Vaccaro, J. V., Young, A. S., & Glynn, S. (1993). Community-based care of individuals with schizophrenia. Psychiatric Clinics of North America, 16, 387-399.
88. Wahl, O. (1997). Consumer experience with stigma: Results of a national survey. Alexandria, VA: NAMI.
89. Weiden, P. J., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57(Suppl 11), 53-60.
90. Zygmunt, A., Emmanuel, M., Weiden, P., & Nathan, K. (1997, October). Effectiveness of olanzapine for vocational rehabilitation outcome in schizophrenia. Paper presented at the American Psychiatric Association Psychiatric Services Meeting, Washington, DC.